Company Filing History:
Years Active: 2003-2012
Title: The Innovative Contributions of Daniel Wermeling in Intranasal Drug Delivery
Introduction: Daniel Wermeling, an accomplished inventor based in Lexington, KY, has made significant strides in the field of pharmaceutical compositions through his innovative contributions. With a total of four patents to his name, Wermeling is dedicated to improving drug delivery methods, particularly in the realm of intranasal administration.
Latest Patents: Among his notable inventions are two significant patents that stand out in the industry. The first, "Intranasal opioid compositions," pertains to pharmaceutical formulations designed for intranasal administration. This innovation includes an effective amount of an opioid combined with a liquid nasal carrier and may also incorporate enhancers such as sweeteners or flavoring agents. Notably, this invention aims to enhance bioavailability and improve patient compliance, offering a more efficient way for individuals to manage pain.
The second patent, "Programmable multi-dose intranasal drug delivery device," introduces a novel apparatus allowing for self-administration of multiple doses of an intranasal liquid pharmaceutical composition. This device is designed to include a series of sealed vials, each containing a measured volume of the composition, and utilizes a pump assembly to deliver the drug as a nasal spray. This innovation not only provides ease of use for patients but also incorporates programmable functions to enhance the user experience, ensuring a timely administration of doses.
Career Highlights: Daniel Wermeling is a notable figure at the University of Kentucky Research Foundation, where he continues to exploit his expertise in pharmaceutical research. His work primarily focuses on optimizing drug delivery systems to enhance therapeutic efficacy and patient adherence.
Collaborations: Throughout his career, Wermeling has collaborated with fellow researchers such as Ryan Vallance and Aravind Balasubramaniam. These partnerships have fostered an environment of innovation, combining diverse expertise to push the boundaries of pharmaceutical research and development.
Conclusion: Daniel Wermeling's contributions to the field of intranasal drug delivery exemplify the potential of innovative thinking in pharmaceuticals. With his recent patents, he is not only addressing critical challenges in pain management but also paving the way for advancements in patient care. His work at the University of Kentucky Research Foundation continues to inspire peers and future inventors alike, solidifying his legacy in pharmaceutical innovation.